A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

NCT04841538 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor's clinical development strategy adjustment

Conditions

Thoracic Tumors
Non-small Cell Lung Cancer
Small Cell Lung Cancer

Interventions

DRUG: ES101

Sponsor

Elpiscience Biopharma, Ltd.